JDJack K. Donohue

Jack K. Donohue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jack K. Donohue has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Post-Thrombotic Syndrome Morbidity in Mechanical Thrombectomy Versus Pharmacomechanical Catheter-Directed Thrombolysis of Iliofemoral Deep Venous Thrombosis

    by Jack K. Donohue, Kevin Li, Anthony Tang, Rachel J. Kann, Lena Vodovotz, Adham N. Abou Ali, Rabih A. Chaer, Natalie D. Sridharan


  • Open Access

    Missingness matters: a secondary analysis of thromboelastography measurements from a recent prehospital randomized tranexamic acid clinical trial

    by Jack K Donohue, Nidhi Iyanna, John M Lorence, Joshua B Brown, Frances X Guyette, Brian J Eastridge, Raminder Nirula, Gary A Vercruysse, Terence O'KEeffe, Bellal Joseph, et al.

    Background Tranexamic acid (TXA) has been hypothesized to mitigate coagulopathy in patients after traumatic injury. Despite previous prehospital clinical trials demonstrating a TXA survival benefit, none have demonstrated correlated changes in thromboelastography (TEG) parameters. We sought to analyze if missing TEG data contributed to this paucity of findings. Methods We performed a secondary analysis of the Study of Tranexamic Acid During Air Medical and Ground Prehospital Transport Trial. We compared patients that received TEG (YES-TEG) and patients unable to be sampled (NO-TEG) to analyze subgroups in which to investigate TEG differences. TEG parameter differences across TXA intervention arms were assessed within subgroups disproportionately present in the NO-TEG relative to the YES-TEG cohort. Generalized linear models controlling for potential confounders were applied to findings with pResults NO-TEG patients had lower prehospital systolic blood pressure (SBP) (100 (78, 140) vs 125 (88, 147), pConclusions Missing data, due to the logistical challenges of sampling certain severely injured patients, may be associated with a lack of TEG parameter changes on TXA administration in the primary analysis. Previous demonstration of TXA’s survival benefit in patients with severe prehospital shock in tandem with the current findings supports the notion that TXA acts at least partially by improving clot integrity. Level of evidence Level II.


  • Lung transplantation in HIV seropositive recipients: An analysis of the UNOS registry

    by Jack K. Donohue, Ernest G. Chan, Sarah Clifford, John P. Ryan, Masashi Furukawa, Ghady Haidar, Alessandro Bertani, Chadi A. Hage, Pablo G. Sanchez

    Background: Experience with lung transplantation (LT) in patients with human immunodeficiency virus (HIV) is limited. Many studies have demonstrated the success of kidney and liver transplantation in HIV‐seropositive (HIV+) patients. Our objective was to conduct a national registry analysis comparing LT outcomes in HIV+ to HIV‐seronegative (HIV−) recipients.Methods: The United Network for Organ Sharing database was queried to identify LTs performed in adult HIV+ patients between 2016 and 2023. Patients with unknown HIV status, multiorgan transplants, and redo transplants were excluded. The primary endpoints were mortality and graft rejection. Survival time was analyzed using Kaplan–Meier analysis.Results: The study included 17 487 patients, 67 of whom were HIV+. HIV+ recipients were younger (59 vs. 62 years, p = .02), had higher pulmonary arterial pressure (28 vs. 25 mm Hg, p = .04), and higher lung allocation scores (47 vs. 41, p = .01) relative to HIV− recipients. There were no differences in graft/recipient survival time between groups. HIV+ recipients had higher rates of post‐transplant dialysis (18% vs. 8.4%, p = .01), but otherwise had similar post‐transplant outcomes to HIV‐recipients.Conclusions: This national registry analysis suggests LT outcomes in HIV+ patients are not inferior to outcomes in HIV− patients and that well‐selected HIV+ recipients can achieve comparable patient and graft survival rates relative to HIV− recipients.


  • Open Access

    Surgical Management of Hook of Hamate Fractures: A Systematic Review of Outcomes

    by Jack K. Donohue, Michael J. Calcaterra, John R. Fowler


  • Socioeconomic factors predict successful supervised exercise therapy completion

    by Jack K. Donohue, Marissa Jarosinski, Katherine M. Reitz, Yekaterina Khamzina, Jonathan Ledyard, Nathan L. Liang, Rabih A. Chaer, Natalie D. Sridharan


  • Open Access

    Immediate Postoperative COVID-19 Infection after Lung Transplantation: A Systematic Review and Case Series

    by Jack K. Donohue, Eric J. Hyzny, Sarah Clifford, Ernest G. Chan, Jenalee Nicole Coster, Masashi Furukawa, Pablo G. Sanchez

    Background: With new variants challenging the effectiveness of preventive measures, we are beginning to recognize the reality that COVID-19 will continue to pose an endemic threat. The manifestations of COVID-19 in lung transplant recipients during index admission are poorly understood with very few cases reported in recent lung transplant recipients. Optimal management of immunosuppression and antiviral therapy in recent transplant recipients is challenging. Methods: We performed a retrospective analysis identifying lung transplant recipients at our institution who contracted COVID-19 in the immediate postoperative period (within index admission). In addition, we performed a systematic review from January 2020 to August 2023 identifying all publications on the PUBMED database regarding COVID-19 infection in lung transplant recipients during index admission. Results: We report four cases of COVID-19 pneumonia in lung transplant recipients in the immediate postoperative period and we describe the clinical course, treatment options, and immunosuppression changes to manage this unique clinical problem. All patients made a full recovery and were eventually discharged home. Within our review of the literature, the most prevalent presenting symptoms were cough, dyspnea, and fatigue. Six (75%) patients decreased or held their antimetabolite. The two most common treatments were monoclonal antibodies (38%) and remdesivir (63%). Conclusion: Although previous literature demonstrates that COVID-19 can be deadly in recent lung transplant recipients, rapid treatment with anti-viral therapy/immunotherapy, deescalating immunosuppression, and treatment of respiratory decompensation with Decadron was effective in our patients.


  • Open Access

    Multiubiquitination of TRPV4 reduces channel activity independent of surface localization

    by William H. Aisenberg, Brett A. McCray, Jeremy M. Sullivan, Erika Diehl, Lauren R. DeVine, Jonathan Alevy, Anna M. Bagnell, Patrice Carr, Jack K. Donohue, Benedikt Goretzki, et al.